Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study

August 27, 2021

MYINFLA™ 0.5 mg has been approved by Health Canada for the reduction of cardiovascular risk in patients with coronary disease

People with coronary disease now have a new treatment option to reduce the risk of cardiovascular events. Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

Led by Dr. Jean-Claude Tardif, the COLCOT clinical trial compared colchicine to a placebo, as a complement to standard therapy, for the prevention of ischemic cardiovascular events in patients having recently experienced a myocardial infarction (also known as a heart attack).

Published in the prestigious New England Journal of Medicine, the results demonstrated the high efficacy of colchicine, which, when added to standard treatment in patients with myocardial infarction, significantly reduces cardiovascular risk.

learn more on the Institute website


Dr. Jean-Claude Tardif

Get all the latest news!

By signing up for our newsletter, you’ll be getting the latest news about the Foundation delivered directly to your inbox.

I’d like to receive the Montreal Heart Institute Foundation’s newsletter.

Please leave this field empty

Manulife triples your donation*!

Give for research. Every donation will be TRIPLED by Manulife*.



*Until December 31, 2021 and up to a maximum of $100,000.

Manulife, Manulife & Stylized M Design, and Stylized M Design are trademarks of The Manufacturers Life Insurance Company and are used by it, and by its affiliates under license. © 2021 The Manufacturers Life Insurance Company. All rights reserved.